1. Pharmacogenetic Analysis of BR
Pharmacogenetic Analysis of BR.21, a Placebo-Controlled Randomized Phase III Clinical Trial of Erlotinib in Advanced Non-small Cell Lung Cancer 
Geoffrey Liu, MD, FRCPC, D. Cheng, MD, PhD, K. Ding, PhD, A. Le Maitre, MSc, N. Liu, MSc, D. Patel, BSc, Z. Chen, MD, PhD, L. Seymour, MD, PhD, F.A. Shepherd, MD, FRCPC, M.S. Tsao, MD, FRCPC 
Journal of Thoracic Oncology 
Volume 7, Issue 2, Pages (February 2012)
DOI: /JTO.0b013e c1
Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2. FIGURE 1
Biospecimens available and analyzed from BR.21 trial. Samples were not available for release because the samples either had been used up in prior translational analyses (e.g., mutational analysis, in situ hybridization, immunohistochemical analysis, and gene expression analyses) or were deemed to have inadequate remaining tissue for the present analysis. Most of these samples were from cases in which slides (rather than blocks) had been provided by the originating pathology department. Failed genotyping refers to failure of the genotyped result to meet quality control standard, including failure of replication during duplicate genotyping or uninterpretable genotyping results despite repeated testing.
Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e c1)
Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions